Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $89.6 million.

  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity fell 720.02% to $89.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.4 million, marking a year-over-year decrease of 85.33%. This contributed to the annual value of $113.2 million for FY2024, which is 1207.59% up from last year.
  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity amounted to $89.6 million in Q3 2025, which was down 720.02% from $90.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity peaked at $174.5 million during Q4 2021, and registered a low of $89.6 million during Q3 2025.
  • For the 5-year period, Lineage Cell Therapeutics' Liabilities and Shareholders Equity averaged around $118.4 million, with its median value being $113.2 million (2023).
  • In the last 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity skyrocketed by 6169.21% in 2021 and then plummeted by 2915.06% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $174.5 million in 2021, then dropped by 29.15% to $123.7 million in 2022, then dropped by 18.31% to $101.0 million in 2023, then rose by 12.08% to $113.2 million in 2024, then dropped by 20.83% to $89.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $89.6 million in Q3 2025, compared to $90.8 million in Q2 2025 and $111.8 million in Q1 2025.